Sussex Formulary
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
    • Sussex-wide protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
    • 2025
    • 2024
    • 2023
  • APC Minutes
    • 2021
    • 2022
    • 2023
    • 2024
    • 2025
    • 2026
  • Discontinuations
  • Contact us
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
      • 11.1 Allergic and inflammatory eye conditions
      • 11.2 Dry eye conditions
      • 11.3 Eye infections
      • 11.4 Eye procedures
        • 11.4.1 Post-operative pain and inflammation
      • 11.5 Glaucoma and ocular hypertension
      • 11.6 Retinal disorders
      • 11.7 Other Eye items
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
  • APC Minutes
  • Discontinuations
  • Contact us
  • Search

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

Bromfenac

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Bromfenac 900micrograms/ml eye drops

Pack
5 ml

Diclofenac

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Diclofenac 0.1% eye drops 0.3ml unit dose preservative free

Pack
5 unit dose
40 unit dose

Ketorolac

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Ketorolac 0.5% eye drops

Pack
5 ml

Loteprednol

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Loteprednol 0.5% eye drops

Pack
5 ml

Oxybuprocaine

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Oxybuprocaine 0.4% eye drops 0.5ml unit dose preservative free

Pack
20 unit dose

Proxymetacaine

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Proxymetacaine causes less initial stinging and is useful in children. It has a short duration of action.

Proxymetacaine 0.5% eye drops 0.5ml unit dose preservative free

Pack
20 unit dose

Tetracaine

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Tetracaine 0.5% eye drops 0.5ml unit dose preservative free

Pack
20 unit dose

Tetracaine 1% eye drops 0.5ml unit dose preservative free

Pack
20 unit dose

Online Formulary by M.O.M. Systems

NICE guidance is available from https://www.nice.org.uk/guidance All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

© Copyright 2026